PSMA Theranostics: Current Landscape and Future Outlook
Introduction: Prostate-specific membrane antigen (PSMA) is a promising novel molecular target for imaging diagnostics and therapeutics (theranostics). There has been a growing body of evidence supporting PSMA theranostics approaches in optimizing the management of prostate cancer and potentially alt...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-08-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/13/16/4023 |
| _version_ | 1797524439042097152 |
|---|---|
| author | Hanbo Zhang Stella Koumna Frédéric Pouliot Jean-Mathieu Beauregard Michael Kolinsky |
| author_facet | Hanbo Zhang Stella Koumna Frédéric Pouliot Jean-Mathieu Beauregard Michael Kolinsky |
| author_sort | Hanbo Zhang |
| collection | DOAJ |
| description | Introduction: Prostate-specific membrane antigen (PSMA) is a promising novel molecular target for imaging diagnostics and therapeutics (theranostics). There has been a growing body of evidence supporting PSMA theranostics approaches in optimizing the management of prostate cancer and potentially altering its natural history. Methods: We utilized PubMed and Google Scholar for published studies, and clinicaltrials.gov for planned, ongoing, and completed clinical trials in PSMA theranostics as of June 2021. We presented evolving evidence for various PSMA-targeted radiopharmaceutical agents in the treatment paradigm for prostate cancer, as well as combination treatment strategies with other targeted therapy and immunotherapy. We highlighted the emerging evidence of PSMA and fluorodeoxyglucose (FDG) PET/CT as a predictive biomarker for PSMA radioligand therapy. We identified seven ongoing clinical trials in oligometastatic-directed therapy using PSMA PET imaging. We also presented a schematic overview of 17 key PSMA theranostic clinical trials throughout the various stages of prostate cancer. Conclusions: In this review, we presented the contemporary and future landscape of theranostic applications in prostate cancer with a focus on PSMA ligands. As PSMA theranostics will soon become the standard of care for the management of prostate cancer, we underscore the importance of integrating nuclear medicine physicians into the multidisciplinary team. |
| first_indexed | 2024-03-10T08:57:25Z |
| format | Article |
| id | doaj.art-50d7f4a92a004719b0fec7eee8f36239 |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-10T08:57:25Z |
| publishDate | 2021-08-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-50d7f4a92a004719b0fec7eee8f362392023-11-22T07:02:37ZengMDPI AGCancers2072-66942021-08-011316402310.3390/cancers13164023PSMA Theranostics: Current Landscape and Future OutlookHanbo Zhang0Stella Koumna1Frédéric Pouliot2Jean-Mathieu Beauregard3Michael Kolinsky4Department of Medical Oncology and Hematology, University of Manitoba, Winnipeg, MB R3E 0V9, CanadaDepartment of Diagnostic Imaging, Cross Cancer Institute, Edmonton, AB T6G 1Z2, CanadaDepartment of Surgery, Université Laval, Québec City, QC G1R 3S1, CanadaDepartment of Radiology and Nuclear Medicine, Université Laval, Québec City, QC G1R 3S1, CanadaDepartment of Medical Oncology, University of Alberta, Edmonton, AB T6G 1Z2, CanadaIntroduction: Prostate-specific membrane antigen (PSMA) is a promising novel molecular target for imaging diagnostics and therapeutics (theranostics). There has been a growing body of evidence supporting PSMA theranostics approaches in optimizing the management of prostate cancer and potentially altering its natural history. Methods: We utilized PubMed and Google Scholar for published studies, and clinicaltrials.gov for planned, ongoing, and completed clinical trials in PSMA theranostics as of June 2021. We presented evolving evidence for various PSMA-targeted radiopharmaceutical agents in the treatment paradigm for prostate cancer, as well as combination treatment strategies with other targeted therapy and immunotherapy. We highlighted the emerging evidence of PSMA and fluorodeoxyglucose (FDG) PET/CT as a predictive biomarker for PSMA radioligand therapy. We identified seven ongoing clinical trials in oligometastatic-directed therapy using PSMA PET imaging. We also presented a schematic overview of 17 key PSMA theranostic clinical trials throughout the various stages of prostate cancer. Conclusions: In this review, we presented the contemporary and future landscape of theranostic applications in prostate cancer with a focus on PSMA ligands. As PSMA theranostics will soon become the standard of care for the management of prostate cancer, we underscore the importance of integrating nuclear medicine physicians into the multidisciplinary team.https://www.mdpi.com/2072-6694/13/16/4023prostate-specific membrane antigentheranosticspositron emission tomographyradioligand therapyprostate cancer |
| spellingShingle | Hanbo Zhang Stella Koumna Frédéric Pouliot Jean-Mathieu Beauregard Michael Kolinsky PSMA Theranostics: Current Landscape and Future Outlook Cancers prostate-specific membrane antigen theranostics positron emission tomography radioligand therapy prostate cancer |
| title | PSMA Theranostics: Current Landscape and Future Outlook |
| title_full | PSMA Theranostics: Current Landscape and Future Outlook |
| title_fullStr | PSMA Theranostics: Current Landscape and Future Outlook |
| title_full_unstemmed | PSMA Theranostics: Current Landscape and Future Outlook |
| title_short | PSMA Theranostics: Current Landscape and Future Outlook |
| title_sort | psma theranostics current landscape and future outlook |
| topic | prostate-specific membrane antigen theranostics positron emission tomography radioligand therapy prostate cancer |
| url | https://www.mdpi.com/2072-6694/13/16/4023 |
| work_keys_str_mv | AT hanbozhang psmatheranosticscurrentlandscapeandfutureoutlook AT stellakoumna psmatheranosticscurrentlandscapeandfutureoutlook AT fredericpouliot psmatheranosticscurrentlandscapeandfutureoutlook AT jeanmathieubeauregard psmatheranosticscurrentlandscapeandfutureoutlook AT michaelkolinsky psmatheranosticscurrentlandscapeandfutureoutlook |